An Exploratory Study on the Interrelation of Breast Cancer Molecular Phenotypes with Breast Cancer-Associated Adipose Tissues (BCAATs), Neoadjuvant, and Adjuvant Therapies: A Focus on Prognosis and Survival
Related Experiment Video
Updated: Aug 5, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Mihaela Maria Pasca Fenesan1,2,3, Razvan George Bogdan1,4, Andrei Alexandru Cosma2,3
1Doctoral School, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Background/Aim:
We previously described four distinct breast cancer (BC)-associated adipose tissue (BCAAT) subtypes that have a significant impact on survival. In this exploratory study, we aimed to determine whether these BCAAT subtypes exhibit significant correlations with neoadjuvant and adjuvant therapies and BC molecular subtypes.
Methods:
Four BCAAT subtypes previously identified as fibroblast-rich (FRich_BCAAT), myofibroblast-rich (MyoFRich_BCAAT), vascular-rich (VRich_BCAAT), and mixed vascular- and inflammation-rich (VIRich_BCAAT) were analyzed according to their distribution in BC molecular subtypes, as well as in relation to neoadjuvant therapy and survival.
Results:
Triple-negative BC and Luminal B (LB) BC are related to VRich and VIRich BCAAT subtypes and were affected by Epirubicin/Cyclophosphamide (EC)+ paclitaxel (PTX) therapy, which significantly enhanced overall survival (OS) and disease-free survival (DFS). For the Luminal A (LA) BC subtype, EC + docetaxel (DTX) had significant impact on survival independent of BCAAT subtype.
Conclusions:
BCAAT subtypes strongly influenced neoadjuvant therapy response and survival depending on BC molecular subtype.
